Hindryckx Pieter, Novak Gregor, Costanzo Antonio, Danese Silvio
a Department of Gastroenterology , University of Ghent , Ghent , Belgium.
b Department of Gastroenterology , University Medical Centre Ljubljana , Ljubljana , Slovenia.
Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):203-214. doi: 10.1080/17474124.2017.1283985. Epub 2017 Feb 1.
Skin manifestations are common in patients with inflammatory bowel diseases (IBD) and can be part of a concomitant illness with a shared genetic background, an extra-intestinal manifestation of the disease, or a drug side-effect. Areas covered: We provide a practical overview of the epidemiology, pathogenesis, diagnosis, therapeutic approach and prognosis of the most frequent disease-related and drug-induced cutaneous manifestations in IBD, illustrated by cases encountered in our clinical practice. Among the most frequently encountered IBD-related lesions are erythema nodosum, pyoderma gangrenosum and Sweet's syndrome. Common skin manifestations with a strong association to TNF antagonists are local injection site reactions, psoriasiform lesions, cutaneous infections, vasculitides and lupus-like syndromes. In addition, we discuss the relation of thiopurines and TNF antagonists with the risk of skin cancer. Expert commentary: We hope this review will help caretakers involved in the management of IBD patients to recognize the lesions and to manage them in close collaboration with a dedicated dermatologist.
皮肤表现在炎症性肠病(IBD)患者中很常见,可能是具有共同遗传背景的伴随疾病的一部分、该疾病的肠外表现或药物副作用。涵盖领域:我们对IBD中最常见的与疾病相关和药物诱导的皮肤表现的流行病学、发病机制、诊断、治疗方法和预后进行了实用概述,并通过我们临床实践中遇到的病例进行说明。在最常遇到的与IBD相关的病变中,有结节性红斑、坏疽性脓皮病和Sweet综合征。与肿瘤坏死因子拮抗剂密切相关的常见皮肤表现是局部注射部位反应、银屑病样病变、皮肤感染、血管炎和狼疮样综合征。此外,我们还讨论了硫唑嘌呤和肿瘤坏死因子拮抗剂与皮肤癌风险的关系。专家评论:我们希望这篇综述将有助于参与IBD患者管理的护理人员识别这些病变,并与专业皮肤科医生密切合作进行管理。